Nanexa AB (publ) (NANEXA.ST)

SEK 2.54

(-5.22%)

Total Liabilities Summary of Nanexa AB (publ)

  • Nanexa AB (publ)'s latest annual total liabilities in 2023 was 36.42 Million SEK , down -40.38% from previous year.
  • Nanexa AB (publ)'s latest quarterly total liabilities in 2024 Q1 was 30.89 Million SEK , down -15.18% from previous quarter.
  • Nanexa AB (publ) reported annual total liabilities of 61.09 Million SEK in 2022, up 345.88% from previous year.
  • Nanexa AB (publ) reported annual total liabilities of 13.7 Million SEK in 2021, up 32.52% from previous year.
  • Nanexa AB (publ) reported quarterly total liabilities of 30.89 Million SEK for 2024 Q1, down -15.18% from previous quarter.
  • Nanexa AB (publ) reported quarterly total liabilities of 50.34 Million SEK for 2023 Q2, down -8.68% from previous quarter.

Annual Total Liabilities Chart of Nanexa AB (publ) (2023 - 2014)

Historical Annual Total Liabilities of Nanexa AB (publ) (2023 - 2014)

Year Total Liabilities Total Liabilities Growth
2023 36.42 Million SEK -40.38%
2022 61.09 Million SEK 345.88%
2021 13.7 Million SEK 32.52%
2020 10.34 Million SEK -2.08%
2019 10.56 Million SEK -9.05%
2018 11.61 Million SEK 103.42%
2017 5.7 Million SEK 57.47%
2016 3.62 Million SEK 109.73%
2015 1.72 Million SEK 54.67%
2014 1.11 Million SEK 0.0%

Peer Total Liabilities Comparison of Nanexa AB (publ)

Name Total Liabilities Total Liabilities Difference
AcuCort AB 10.97 Million SEK -231.909%
AlzeCure Pharma AB (publ) 8.22 Million SEK -342.774%
BioGaia AB (publ) 302.84 Million SEK 87.972%
Enzymatica AB (publ) 49.3 Million SEK 26.115%
Enorama Pharma AB (publ) 14.84 Million SEK -145.349%
Gabather AB (publ) 6.87 Million SEK -429.616%
Klaria Pharma Holding AB (publ.) 31.98 Million SEK -13.884%
Moberg Pharma AB (publ) 24 Million SEK -51.735%
Newbury Pharmaceuticals AB (publ) 38.95 Million SEK 6.487%
ODI Pharma AB 10.05 Million SEK -262.181%
Orexo AB (publ) 727.7 Million SEK 94.994%
Probi AB (publ) 181.31 Million SEK 79.91%
Swedencare AB (publ) 2.31 Billion SEK 98.427%
Swedish Orphan Biovitrum AB (publ) 40.16 Billion SEK 99.909%
Toleranzia AB 6.9 Million SEK -427.24%
Vivesto AB 30.45 Million SEK -19.621%